A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Recruiting · Phase 3 · NCT07321886
Conditions: Obesity, Overweight
At a glance
- Research payments reported, 2025
- $95
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 1,980
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Eloralintide (drug), Placebo (drug)
- Dates
- Started 2026-02-06; completion 2030-07
- Results posted
- Not yet
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
From ClinicalTrials.gov, last updated 2026-09-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $95 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- American Research Centers $95
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.